- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Citing Suspected Vaccine Patent Infringement, GSK Files Lawsuit Against Pfizer
Company is seeking monetary damages from the alleged violation.
Believing the multinational company violated four patents relating to the use of Antigens in Arexvy, GSK has announced the filing of a lawsuit against Pfizer. According to the documents filed in court, Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, was created with GSK’s “claimed inventions”. With GSK seeking monetary damages such as lost profits, Pfizer has denied any infringement, planning to defend its work.
As both Arexvy and Abrysvo have already received FDA approval, doses are now available to the public for use in adults over 60. As a part of legal proceedings, GSK has requested authorities to prevent Pfizer from selling its product.
Reference: GSK Sues Pfizer for Alleged RSV Vaccine Patent Infringement. BioSpace. August 2, 2023. Accessed August 3, 2023. https://www.biospace.com/article/gsk-sues-pfizer-for-alleged-rsv-vaccine-patent-infringement/?s=89
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
